Chronic Spontaneous Urticaria (CSU)

1. Zuberbier, T., et al., The international EAACI/GA(2)LEN/EuroGuiDerm/AP AAACI guideline for the definition, classification, diagnosis, and management of urticaria.

Allergy, 2022. 77(3): p. 734-766.

2. Greaves, M., Chronic urticaria. J Allergy Clin Immunol, 2000. 105(4): p. 664-72.

3. Kolkhir, P., et al., Urticaria. Nat Rev Dis Primers, 2022. 8(1): p. 61.

4. Buttgereit, T., et al., Patients With Chronic Spontaneous Urticaria Who Have Wheals,

Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment

Results From CURE. J Allergy Clin Immunol Pract, 2023. 11(11): p. 3515-3525 e4.

5. Balp, M.M., et al., Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted

Literature Review. Dermatol Ther (Heidelb), 2022. 12(1): p. 15-27.

6. Sussman, G., et al., Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU. Allergy, 2018. 73(8): p. 1724- 1734.

7. Kovalkova, E., et al., Comorbid Inducible Urticaria Is Linked to Non-Autoimmune

Chronic Spontaneous Urticaria: CURE Insights. J Allergy Clin Immunol Pract, 2024.

12(2): p. 482-490 e1.

8. Sijapati, N., et al., Exercise-Induced Urticaria: A Rare Case Report. Cureus, 2022. 14(3): p.

e23062.

9. V olcheck, G.W. and J.T. Li, Exercise-induced urticaria and anaphylaxis. Mayo Clin Proc,

1997. 72(2): p. 140-7.

10. Kulthanan, K., et al., Food-dependent cold urticaria: A new variant of physical urticaria. J Allergy Clin Immunol Pract, 2018. 6(4): p. 1400-1402.

11. Maurer, M., et al., Efficacy and safety of omalizumab in patients with chronic urticaria

who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol, 2011. 128(1): p. 202-

209 e5.

12. Kolkhir, P., et al., Autoimmune chronic spontaneous urticaria. Journal of Allergy and

Clinical Immunology, 2022. 149(6): p. 1819-1831.

13. Schoepke, N., et al., Biomarkers and clinical characteristics of autoimmune chronic

spontaneous urticaria: Results of the PURIST Study. Allergy, 2019. 74(12): p. 2427-

2436.

14. Asero, R., et al., Activation of the tissue factor pathway of blood coagulation in patients

with chronic urticaria. J Allergy Clin Immunol, 2007. 119(3): p. 705-10.

15. Saini, S.S., et al., Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. J Invest Dermatol, 2017. 137(4): p. 958-961.

16. Shakouri, A., et al., Effectiveness of Helicobacter pylori eradication in chronic urticaria:

evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol, 2010. 10(4): p. 362-9.

17. Confino-Cohen, R., et al., Chronic urticaria and autoimmunity: associations found in a

large population study. J Allergy Clin Immunol, 2012. 129(5): p. 1307-13.

18. Viracor, E. CU Index. 2013 12/APR/2024]; Available from: https://www.eurofins

viracor.com/clinical/test-menu/2103-cu-index/.

19. Biagtan, M.J., et al., Clinical utility of the Chronic Urticaria Index. J Allergy ClinImmunol, 2011. 127(6): p. 1626-7.

20. Sabroe, R.A., et al., British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021. Br J Dermatol, 2022. 186(3): p. 398-413.

21. Kulthanan, K., et al., Chronic idiopathic urticaria: prevalence and clinical course. J

Dermatol, 2007. 34(5): p. 294-301.

22. Siles, R., M. Xu, and F.H. Hsieh, The utility of serum tryptase as a marker in chronic

spontaneous urticaria. Acta Derm Venereol, 2013. 93(3): p. 354-5.

23. Ferrer, M., et al., Serum total tryptase levels are increased in patients with active chronic

urticaria. Clin Exp Allergy, 2010. 40(12): p. 1760-6.

24. Kasperska-Zajac, A., et al., Plasma IL-6 concentration correlates with clinical disease

activity and serum C-reactive protein concentration in chronic urticaria patients. Clin

Exp Allergy, 2011. 41(10): p. 1386-91.

25. Powell, R.J., et al., BSACI guideline for the management of chronic urticaria and

angioedema. Clin Exp Allergy, 2015. 45(3): p. 547-65.

26. Brown, T., J. Gonzalez, and C. Monteleone, Angiotensin-converting enzyme inhibitor

induced angioedema: A review of the literature. J Clin Hypertens (Greenwich), 2017.

19(12): p. 1377-1382.

27. Pfaar, O., et al., COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society

for Applied Allergology (AeDA). Allergol Select, 2021. 5: p. 140-147.

28. Kocaturk, E., et al., Effects of pregnancy on chronic urticaria: Results of the PREG-CU

UCARE study. Allergy, 2021. 76(10): p. 3133-3144.

29. Khan, D.A., Alternative agents in refractory chronic urticaria: evidence and

considerations on their selection and use. J Allergy Clin Immunol Pract, 2013. 1(5): p.

433-440 e1.

30. Bernstein, J.A., et al., The diagnosis and management of acute and chronic urticaria:

2014 update. J Allergy Clin Immunol, 2014. 133(5): p. 1270-7.

31. Kaplan, A.P., Therapy of chronic urticaria: a simple, modern approach. Ann Allergy

Asthma Immunol, 2014. 112(5): p. 419-25.

32. Kallen, B., Use of antihistamine drugs in early pregnancy and delivery outcome. J

Matern Fetal Neonatal Med, 2002. 11(3): p. 146-52.

33. Saini, S., et al., A randomized, placebo-controlled, dose-ranging study of single-dose

omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J

Allergy Clin Immunol, 2011. 128(3): p. 567-73 e1.

34. Metz, M., et al., Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol, 2020. 59(1): p. 38-45.

35. Metz, M., et al., Omalizumab is an effective and rapidly acting therapy in difficult-to treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci, 2014. 73(1): p. 57-62.

36. Barron, C., Saperia, C., Kobric, D., Sussman, G.L., Chronic spontaneous urticaria; Centres' of excellence. Journal of Allergy and Clinical Immunology, 2017. 139(2).

37. EAACI/ESCD Skin Allergy Meeting 2017. Clin Transl Allergy, 2017. 7(47).

38. Vadasz, Z., et al., Omalizumab for severe chronic spontaneous urticaria: Real-lifeexperiences of 280 patients. J Allergy Clin Immunol Pract, 2017. 5(6): p. 1743-1745.

39. Alizadeh Aghdam, M., et al., High-dose omalizumab use in patients with chronic

spontaneous urticaria. J Allergy Clin Immunol Pract, 2020. 8(4): p. 1426-1427 e1.

40. Kocaturk, E., et al., Omalizumab Updosing for Better Disease Control in Chronic

Spontaneous Urticaria Patients. Int Arch Allergy Immunol, 2018. 177(4): p. 360-364.

41. Curto-Barredo, L., et al., Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol, 2018. 179(1): p. 210-212.

42. Salman, A. and E. Comert, The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria. J Cutan Med Surg, 2019. 23(5): p. 496-500.

43. Zhao, Z.T., et al., Omalizumab for the treatment of chronic spontaneous urticaria: A

meta-analysis of randomized clinical trials. J Allergy Clin Immunol, 2016. 137(6): p.

1742-1750 e4.

44. Maurer, M., et al., Omalizumab for the treatment of chronic idiopathic or spontaneous

urticaria. N Engl J Med, 2013. 368(10): p. 924-35.

45. Kaplan, A., et al., Omalizumab in patients with symptomatic chronic

idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin

Immunol, 2013. 132(1): p. 101-9.

46. Urgert, M.C., et al., Omalizumab in patients with chronic spontaneous urticaria: a

systematic review and GRADE assessment. Br J Dermatol, 2015. 173(2): p. 404-15.

47. Saini, S.S., et al., Efficacy and Safety of Omalizumab in Patients with Chronic

Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A

Randomized, Placebo-Controlled Study. J Invest Dermatol, 2015. 135(3): p. 925.

48. Staubach, P., et al., Effect of omalizumab on angioedema in H1 -antihistamine-resistant

chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.

Allergy, 2016. 71(8): p. 1135-44.

49. Metz, M., Staubach, P., Bauer, A., Brehler, R. , Omalizumab normalizes levels of high

affinity immunoglobulin E receptor-positive skin cells in patients with chronic

spontaneous urticaria: a randomized, double-blind, placebo-controlled study. J of

Investigative Derm, 2014. 134: p. S30-38.

50. Namazy, J., et al., The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol, 2015. 135(2): p. 407-12.

51. Kulthanan, K., et al., Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis

and Systematic Review. J Allergy Clin Immunol Pract, 2018. 6(2): p. 586-599.

52. Zimmerman, A.B., et al., The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol, 2012. 66(5): p. 767-70.

53. Sand, F.L. and S.F. Thomsen, Off-label use of TNF-alpha inhibitors in a dermatological

university department: retrospective evaluation of 118 patients. Dermatol Ther, 2015.

28(3): p. 158-65.

54. Bernstein, J.A., S.M. Garramone, and E.G. Lower, Successful treatment of autoimmune

chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma

Immunol, 2002. 89(2): p. 212-4.

55. Pho, L.N., et al., Treatment of chronic urticaria with colchicine. J Drugs Dermatol, 2011.10(12): p. 1423-8.

56. Kalogeromitros, D., et al., Theophylline as 'add-on' therapy to cetirizine in patients with

chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study.

Int Arch Allergy Immunol, 2006. 139(3): p. 258-64.

57. Asero, R., A. Tedeschi, and M. Cugno, Heparin and tranexamic Acid therapy may be

effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int

Arch Allergy Immunol, 2010. 152(4): p. 384-9.

58. Bressler, R.B., K. Sowell, and D.P. Huston, Therapy of chronic idiopathic urticaria with

nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled,

crossover trial. J Allergy Clin Immunol, 1989. 83(4): p. 756-63.

59. Rorie, A., et al., Beneficial role for supplemental vitamin D3 treatment in chronic

urticaria: a randomized study. Ann Allergy Asthma Immunol, 2014. 112(4): p. 376-82.

60. Maurer, M., et al., Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. The Lancet, 2024. 403(10422): p. 147-159.

61. ClinicalTrials.gov. A study of long-term effects of fenebrutinib treatment in patients with

chronic spontaneous urticaria. 2020 07/NOV/2024]; Available from:

https://clinicaltrials.gov/study/NCT03693625.

62. Genentech. Fenebrutinib multiple sclerosis clinical trial program update. 2023

07/NOV/2024]; Available from: https://www.gene.com/media/statements/ps_113023.

63. Metz, M., Gimenez-Amau, A., Hide, M., et al. . Long-term efficacy and safety of

remibrutinib in patietns with chronic spontaneous urticaria in the phase 3 REMIX-1 and

REMIX-2 studies. in EAACI. 2024. Valencia, Spain.

64. Jain, V ., et al., Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. Journal of Allergy and Clinical

Immunology, 2024. 153(2): p. 479-486.e4.

65. Maurer, M., et al., Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria

Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial. Journal of

Allergy and Clinical Immunology, 2024. 153(2): p. AB366.

66. Altrichter, S., Gimenez-Arnau, A.M., Bernstein, J.A. et al, Benralizumab does not elicit

therapeutic effect in patients with chronic spontaneous urticaria: Results form the phase

IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J

Dermatol, 2024. 191(2): p. 187-199.

67. ClinicalTrials.gov. A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines

(ARROYO). 13/APR/2024 11/NOV/2024].

68. Maurer, M., et al., Dupilumab in patients with chronic spontaneous urticaria (LIBERTY CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of

Allergy and Clinical Immunology, 2024. 154(1): p. 184-194.

69. Kudlaty, E., Newell, P., Chovatiya, R., et al., Dupilumab as add-on therapy for

management of chronic spontaneous urticaria. J Clin Aesthet Dermatol, 2024. 17: p. 10-

12.

70. Altrichter, S., Staubach, P., Pasha, M. et al, An open-label, proof-of-concept study of

lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. JAller Clin Immunol, 2022. 149(5): p. 1683-1690.

71. Bakay, O.S.K., Kacar, N., Combined treatment with omalizumab and secukinumab in a

patient with chronic spontaneous urticaria and psoriasis. Dermatol Ther, 2022. 35(9).

72. Sabag, D.A., Matanes, L., Bejar, J. et al, Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy, 2020. 50(7): p. 799-804.

73. Hatlen M, Haidle A, Wilson D, et al. BLU-808: A potent and selective oral small molecule wild-type KIT tyrosine kinase inhibitor for allergic conditions. Poster presented at: American Academy of Allergy Asthma & Immunology (AAAAI) / World Allergy Organization (WAO)

Joint Congress; March 1, 2025; San Diego, CA, USA

74. Casale TB. Briquilimab demonstrates rapid, clinically meaningful reduction in disease

activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study. Presented at: American Academy of Dermatology (AAD) Annual Meeting; March 8, 2025; Orlando, FL.